Loading
CUL3 (Cullin-3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Non-small-cell lung cancer and Papillary renal cell carcinoma.
Core component of multiple cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins. BCR complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins. As a scaffold protein may contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Platinum Doublet. Open Targets scores its association with cancer at 0.55 (direct and indirect evidence; datatypes literature 0.95, animal model 0.56, genetic association 0.03, somatic mutation 0.71). IntOGen calls it a driver in 4 cohorts (1 activating, 3 loss-of-function), covering Lung Squamous Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma.
In plain words · CUL3 (Cullin-3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Non-small-cell lung cancer and Papillary renal cell carcinoma.
CUL3 (Cullin-3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Non-small-cell lung cancer and Papillary renal cell carcinoma.
Core component of multiple cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins.
No product in this corpus aims at CUL3 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CUL3: RNA tissue enhanced (testis 193 nTPM); high antibody staining in 23 normal tissues; highest cancer staining stomach cancer (12 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Renal cell carcinoma, Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q13618; CIViC gene CUL3; IntOGen CUL3; Human Protein Atlas CUL3 tissue; Open Targets ENSG00000036257 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Kipreos E.T. et al, Cell, 1996, "cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family". Source.
Sources: HGNC HGNC:2553 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q13618 (protein name, function text, keywords and locations (REST API)); CIViC gene CUL3 (1 evidence items, 0 assertions, 1 variants; diseases: Lung Non-small Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000036257 (association with cancer (MONDO_0004992) 0.55; (GraphQL API, CC0)); IntOGen CUL3 (driver in 4 cohorts (Act 1, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Core component of multiple cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins. BCR complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins. As a scaffold protein may contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme. The E3 ubiquitin-protein ligase activity of the complex is dependent on the neddylation of the cullin subunit and is inhibited by the association of the deneddylated cullin subunit with TIP120A/CAND1. The functional specificity of the BCR complex depends on the BTB domain-containing protein as the substrate recognition component. BCR(KLHL42) is involved in ubiquitination of KATNA1. Location: Nucleus; Golgi apparatus; Cell projection, cilium, flagellum; Cytoplasm, cytoskeleton, spindle (UniProt). Locus 2q36.2 (HGNC).
RNA: tissue enhanced (testis 193 nTPM), detected in all normal tissues.
Medium: Cerebral cortex, Cervix, Duodenum, Endometrium, Esophagus, Fallopian tube, Gallbladder, Heart muscle.
Medium only: head and neck cancer, thyroid cancer.
HPA CUL3 tissue · HPA CUL3 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CUL3" OR ABSTRACT:"CUL3" OR TITLE:"cullin 3" OR ABSTRACT:"cullin 3" OR TITLE:"Cullin-3" OR ABSTRACT:"Cullin-3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CUL3, not a curated reading list.
Shares Papillary renal cell carcinoma, Renal cell carcinoma, CIViC, IntOGen.
Shares Papillary renal cell carcinoma, Renal cell carcinoma, CIViC, IntOGen.
Shares Papillary renal cell carcinoma, Renal cell carcinoma, CIViC, IntOGen.
Shares Papillary renal cell carcinoma, Renal cell carcinoma, IntOGen.
Shares Papillary renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Papillary renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Papillary renal cell carcinoma, CIViC.
Shares Papillary renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.